Prof. Ugur Sahin, CEO and Co-Founder of BioNTech: “We at BioNTech are saddened by the tragic loss of many lives as a result of the earthquakes that hit Türkiye and Syria. At the same time, the humanitarian situation across Ukraine remains dire. Our thoughts are with all those who have lost loved ones. We are thankful for the first responders and those who are continuously working to save lives and support people affected. We would like to contribute to the humanitarian aid in Türkiye and Syria by donating 500,000 Euro to the nonprofit organization ‘Aktionsbündnis Katastrophenhilfe’ (Action Alliance for Disaster Relief) as well as 500,000 Euro to the refugee relief ‘UNO-Flüchtlingshilfe’ – the partner of UN Refugee Agency (UNHCR) in Germany. We continue to monitor the situation closely, also with regards to our Turkish employees and offer individual help if needed. In the name of the whole management board, I also thank our colleagues in these special situations, who support as volunteers and take part in donation campaigns.”
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, please visit www.BioNTech.com
+49 (0)6131 9084 1513
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074